Schwartz G - Search Results

1

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK. Tolcher AW, et al. Among authors: schwartz g. J Clin Oncol. 2003 Jan 15;21(2):211-22. doi: 10.1200/JCO.2003.05.137. J Clin Oncol. 2003. PMID: 12525512 Clinical Trial.

2

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, Rowinsky EK. Hao D, et al. Clin Cancer Res. 2003 Jul;9(7):2465-71. Clin Cancer Res. 2003. PMID: 12855619 Clinical Trial.

3

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Schwartz GH, Jones CB, Garrison M, Patnaik A, Takimoto C, McCreery H, Skinner M, Tolcher AW, Rowinsky EK. Schwartz GH, et al. Invest New Drugs. 2004 Nov;22(4):437-48. doi: 10.1023/B:DRUG.0000036686.86700.a9. Invest New Drugs. 2004. PMID: 15292714 Clinical Trial.

4

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.

Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, Von Hoff DD, Rowinsky EK. Schwartz GH, et al. Ann Oncol. 2003 May;14(5):775-82. doi: 10.1093/annonc/mdg215. Ann Oncol. 2003. PMID: 12702533 Free article. Clinical Trial.

5

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, Denis L, McGuire J, Tolcher AW. Rowinsky EK, et al. Among authors: schwartz g. J Clin Oncol. 2003 Jan 1;21(1):148-57. doi: 10.1200/JCO.2003.03.143. J Clin Oncol. 2003. PMID: 12506184 Clinical Trial.

6

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Garrison MA, Hammond LA, Geyer CE Jr, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK. Garrison MA, et al. Among authors: schwartz g. Clin Cancer Res. 2003 Jul;9(7):2527-37. Clin Cancer Res. 2003. PMID: 12855627 Clinical Trial.

7

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK. Patnaik A, et al. Among authors: schwartz g. Clin Cancer Res. 2003 Oct 15;9(13):4761-71. Clin Cancer Res. 2003. PMID: 14581347 Clinical Trial.

8

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK. Forouzesh B, et al. Among authors: schwartz g. Clin Cancer Res. 2003 Nov 15;9(15):5540-9. Clin Cancer Res. 2003. PMID: 14654534 Clinical Trial.

9

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. Chu QS, et al. Among authors: schwartz g. Clin Cancer Res. 2004 Aug 1;10(15):4913-21. doi: 10.1158/1078-0432.CCR-04-0469. Clin Cancer Res. 2004. PMID: 15297391 Clinical Trial.

10

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. Tolcher AW, et al. Among authors: schwartz g. Clin Cancer Res. 2004 Aug 1;10(15):5048-57. doi: 10.1158/1078-0432.CCR-03-0701. Clin Cancer Res. 2004. PMID: 15297406 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,419 results

Search Page

Filters